

add 200 mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of cefalexin is about 7 minutes.

System suitability—


System performance: When the procedure is run with 10 μ L of the standard solution under the above operating conditions, cefalexin and the internal standard are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 5 times with 10 μ L of the standard solution under the above operating conditions, the relative standard deviation of the ratios of the peak area of cefalexin to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Tight containers.

Cefaloridine

セファロリジン



$C_{19}H_{17}N_3O_4S_2$: 415.49

(6*R*,7*R*)-8-Oxo-3-(pyridinium-1-ylmethyl)-7-[(thiophen-2-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [50-59-9]


Cefaloridine conforms to the requirements of Cefaloridine in the Requirements for Antibiotic Products of Japan.

Description Cefaloridine occurs as a white to light yellowish white crystals or crystalline powder.

It is soluble in water, slightly soluble in methanol, very slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Cefalotin Sodium

セファロチンナトリウム



$C_{16}H_{15}N_2NaO_6S_2$: 418.42

Monosodium (6*R*,7*R*)-3-acetoxymethyl-8-oxo-7-[2-(thiophen-2-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [58-71-9]


Cefalotin Sodium conforms to the requirements of Cefalotin Sodium in the Requirements for Antibiotic Products of Japan.

Description Cefalotin Sodium occurs as a white to yellowish white crystals or crystalline powder.

It is freely soluble in water, slightly soluble in methanol, very slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Cefamandole Sodium

セファマンドールナトリウム



$C_{18}H_{17}N_6NaO_5S_2$: 484.48

Monosodium (6*R*,7*R*)-7-[(2*R*)-2-hydroxy-2-phenylacetyl]amino]-3-(1-methyl-1*H*-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [30034-03-8]


Cefamandole Sodium conforms to the requirements of Cefamandole Sodium in the Requirements for Antibiotic Products of Japan.

Description Cefamandole Sodium occurs as a white to light yellowish white crystalline powder. It has a slightly bitter taste.

It is freely soluble in water, soluble in methanol, slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Cefapirin Sodium

セファピリンナトリウム



$C_{17}H_{16}N_3NaO_6S_2$: 445.45

Monosodium (6*R*,7*R*)-3-acetoxymethyl-8-oxo-7-[2-(pyridin-4-ylsulfanyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [24356-60-3]

Cefapirin Sodium contains not less than 865 μ g (potency) per mg, calculated on the anhydrous basis. The potency of Cefapirin Sodium is expressed as mass (potency) of cefapirin ($C_{17}H_{17}N_3O_6S_2$: 423.47).

Description Cefapirin Sodium occurs as a white to yellowish white powder.

It is freely soluble in water, sparingly soluble in methanol, very slightly soluble in ethanol (95), and practically insoluble in acetone.

Identification (1) Determine the absorption spectrum of a solution of Cefapirin Sodium (3 in 200,000) as directed under the Ultraviolet-visible Spectrophotometry, and compare the spectrum with the Reference Spectrum or the spectrum of Cefapirin Sodium Reference Standard: both spectra exhibit similar intensities of absorption at the same wavelength.

(2) Determine the infrared absorption spectrum of Cefapirin Sodium as directed in the potassium bromide disk method under the Infrared Spectrophotometry, and compare the spectrum with the Reference Spectrum or the spectrum of Cefapirin Sodium Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) Determine the spectrum of a solution of Cefapirin Sodium in heavy water for nuclear magnetic resonance spectroscopy (1 in 10), using sodium 3-(trimethylsilyl)propionate- d_4 for nuclear magnetic resonance spectroscopy as an internal reference compound, as directed under the Nuclear Magnetic Resonance Spectroscopy (^1H): it exhibits a single signal A at around δ 2.2 ppm, and multiple signals, B and C, at around δ 7.3 ppm and at around δ 8.3 ppm, respectively. The ratio of integrated intensity of these signals, A:B:C, is about 3:2:2.

(4) Cefapirin Sodium responds to the Qualitative Test (1) for sodium salt.

Optical rotation $[\alpha]_D^{25}$: +157 – +175° (2 g calculated as the anhydrous basis, water, 100 mL, 100 mm).

pH Dissolve 1.0 g of Cefapirin Sodium in 10 mL of water: pH of the solution is between 6.5 and 8.5.

Purity (1) Heavy metals—Proceed with 1.0 g of Cefapirin Sodium according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) **Arsenic**—Prepare the test solution with 1.0 g of Cefapirin Sodium according to Method 3, and perform the test using Apparatus B (not more than 2 ppm). Use a solution of magnesium nitrate hexahydrate in ethanol (95) (1 in 25).

(3) **Related substances**—Dissolve 0.1 g of Cefapirin Sodium in 5 mL of a mixture of acetone and water (3:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add a mixture of acetone and water (3:1) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under the Thin-layer Chromatography. Spot 5 μL each of the sample solution and the standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop with a mixture of ethyl acetate, acetone, water and acetic acid (100) (5:2:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the spots other than the principal spot and other than the spot at the original point from the sample solution are not more intense than the spot from the standard solution.

Water Not more than 2.0% (0.7 g, volumetric titration, direct titration).

Assay Weigh accurately an amount of Cefapirin Sodium and Cefapirin Sodium Reference Standard equivalent to about 0.1 g (potency), dissolve each in phosphate buffer solution, pH 6.0 to make exactly 100 mL. Pipet 5 mL of each so-

lution, add exactly 5 mL of the internal standard solution and phosphate buffer solution, pH 6.0 to make 100 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with 20 μL each of the sample solution and the standard solution as directed under the Liquid Chromatography according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of cefapirin to that of the internal standard.

Amount [μg (potency)] of cefapirin ($\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_6\text{S}_2$)
= amount [mg (potency)] of Cefapirin Sodium

$$\text{Reference Standard} = \frac{Q_T}{Q_S} \times 1000$$

Internal standard solution—A solution of vanillin (1 in 1000).

Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of 0.05 mol/L sodium dihydrogenphosphate TS, pH 2.6 and acetonitrile (93:7).

Flow rate: Adjust the flow rate so that the retention time of cefapirin is about 7 minutes.

System suitability—


System performance: When the procedure is run with 20 μL of the standard solution under the above operating conditions, cefapirin and the internal standard are eluted in this order with the resolution between these peaks being not less than 10.

System repeatability: When the test is repeated 6 times with 20 μL of the standard solution under the above operating conditions, the relative standard deviation of the ratios of the peak area of cefapirin to that of the internal standard is not more than 1.0%.

Containers and storage Containers—Hermetic containers.

Cefatrizine Propylene Glycolate

セファトリジンプロピレングリコール



$\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_2 \cdot \text{C}_3\text{H}_8\text{O}_2$; 538.60

(6*R*,7*R*)-7-[(2*R*)-2-Amino-2-(4-hydroxyphenyl)acetylamino]-8-oxo-3-[2(1*H*-1,2,3-triazol-4-yl)sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monopropane-1,2-diolate (1/1) [51627-14-6, Cefatrizine]

Cefatrizine Propylene Glycolate contains not less than 785 μg (potency) per mg, calculated on the anhydrous basis. The potency of Cefatrizine Propylene